Candel Therapeutics, Inc. (CADL)

NGM – Real Time Price. Currency in USD

10.68

+0.03 (0.28%)

At close: Aug 12, 2026, 4:00 PM EDT

10.68

0.00 (0.00%)

After-hours: Aug 12, 2026, 4:01 PM EDT

07.08.2026

Candel Therapeutics: Getting Closer, And Building Out More Paths

Candel Therapeutics, Inc. remains a Buy as its lead asset, CAN-2409, advances toward FDA submission in prostate cancer with strong phase 3 data. CADL is well-capitalized, holding $194.8M in cash, providing runway into Q1 2028 and supporting pivotal trials in prostate and lung cancer. CAN-2409's phase 3 prostate cancer trial, conducted under Special Protocol Assessment, positions CADL for a potentially smoother regulatory review.

03.08.2026

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on July 31, 2026, the Compensation Committee of Candel's Board of Directors (the Board) granted to three new employees, stock options to purchase an aggregate of 30,800 shares of the Company's common stock, with a per share exercise price of $10.01.

03.08.2026

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that an abstract was accepted for poster presentation at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place September 26-30, 2026, in Boston, MA.

Videos

No Data

There is no data to display

Press releases

03.08.2026

Candel Therapeutics, Inc. (CADL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Candel Therapeutics, Inc. (CADL)

Candel Therapeutics: Getting Closer, And Building Out More Paths

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

Videos

No Data

Press releases

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics: Getting Closer, And Building Out More Paths

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

Videos

No Data

Press releases

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Candel Therapeutics, Inc. (CADL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Candel Therapeutics, Inc. (CADL)

Candel Therapeutics: Getting Closer, And Building Out More Paths

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

Videos

No Data

Press releases

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics: Getting Closer, And Building Out More Paths

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

Videos

No Data

Press releases

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)